Riliprubart Market Summary

Key Factors Driving Riliprubart Growth

1. Large unmet need in CIDP: Riliprubart is being developed for chronic inflammatory demyelinating polyneuropathy (CIDP), where Sanofi estimates that ~30% of patients do not respond to standard therapies, while among responders, about 70% have an incomplete response. Fewer than one-third of patients remain in remission without continued treatment. This persistent need creates an opportunity for a new mechanism and treatment approach.

2. Novel complement-targeted mechanism: Riliprubart (SAR445088/BIVV020) is an IgG4 humanized monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway. By blocking C1s, it is intended to reduce inflammatory mechanisms contributing to demyelination and axonal injury. This mechanism differentiates it from established CIDP therapies such as IVIg, corticosteroids and plasma exchange.

3. Encouraging Phase 2 efficacy and biomarker results: In the Phase II study, 87% (42/48) of standard-of-care-treated patients improved or remained stable after 24 weeks of switching to riliprubart, while 89% (16/18) of standard-of-care-refractory patients improved or remained stable. Riliprubart also produced a 35% reduction in neurofilament light chain (NfL) through 48 weeks, a biomarker associated with neuroaxonal damage. At 76 weeks, 80% of evaluable standard-of-care-treated patients remained relapse-free, while 78% of evaluable refractory patients had sustained responses.

4. Potential convenience of subcutaneous administration: Phase II data presented by Sanofi indicate that riliprubart can be self-administered subcutaneously at home. If efficacy is confirmed, a convenient subcutaneous regimen could provide an alternative to treatment approaches requiring repeated infusions or other healthcare-resource-intensive administration, potentially supporting patient acceptance and persistence.

5. Broad regulatory recognition: Riliprubart has received orphan-drug designations in the U.S., Europe and Japan, and Japan's MHLW granted orphan designation for CIDP in 2025. Sanofi reported approximately 4,000 diagnosed CIDP patients in Japan alone. The program also received Breakthrough Therapy designation in China, strengthening the regulatory-development pathway across multiple major markets.

Riliprubart Recent Developments

In June 2026, Sanofi announced that the Riliprubart MOBILIZE Phase III study (clinical study identifier: NCT06290128) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) refractory to standard-of-care treatment will be stopped. This decision follows an interim analysis by an independent data monitoring committee, which determined that the MOBILIZE study is unlikely to provide sufficient efficacy. No safety signals related to riliprubart were identified as part of this interim analysis. The continuation of other ongoing studies with riliprubart, including the VITALIZE Phase III study (clinical study identifier: NCT06290141) in IVIg-treated patients with CIDP, will be evaluated accordingly.

“Riliprubart Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Riliprubart for potential indication like Chronic inflammatory demyelinating polyradiculoneuropathy in the 7MM. A detailed picture of Riliprubart’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Riliprubart for potential indications. The Riliprubart market report provides insights about Riliprubart’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Riliprubart performance, future market assessments inclusive of the Riliprubart market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Riliprubart sales forecasts, along with factors driving its market.

Riliprubart Drug Summary

Riliprubart is an investigational IgG4 humanized monoclonal antibody that selectively inhibits activated C1s, a key component of the classical complement pathway of the innate immune system. By blocking C1s, riliprubart is designed to suppress complement-mediated inflammation and tissue injury, with potential applications in immune-mediated disorders such as chronic inflammatory demyelinating polyneuropathy (CIDP) and antibody-mediated rejection (AMR) following kidney transplantation. In CIDP, inhibition of C1s may reduce complement-driven damage to peripheral-nerve myelin and axons. Riliprubart is being developed by Sanofi and is administered by subcutaneous injection, with clinical development focused on providing a potentially less burdensome alternative to repeated intravenous immunoglobulin (IVIg) therapy. As of 2026, riliprubart remains investigational and has not received regulatory approval. Sanofi is evaluating it in the Phase 3 VITALIZE study in IVIg-treated adults with CIDP, while the Phase 3 MOBILIZE study in patients with CIDP refractory to standard treatment was discontinued in June 2026 after an interim analysis indicated that it was unlikely to demonstrate sufficient efficacy; Sanofi reported no riliprubart-related safety signal in that analysis. Riliprubart is also being investigated in kidney transplantation for the prevention and treatment of AMR, and received U.S. FDA orphan-drug designation for this indication in 2025. The report provides Riliprubart’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Riliprubart Market Report

The report provides insights into:

• A comprehensive product overview including the Riliprubart MoA, description, dosage and administration, research and development activities in potential indication like Chronic inflammatory demyelinating polyradiculoneuropathy.
• Elaborated details on Riliprubart regulatory milestones and other development activities have been provided in Riliprubart market report.
• The report also highlights Riliprubart‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Riliprubart market report also covers the patents information, generic entry and impact on cost cut.
• The Riliprubart market report contains current and forecasted Riliprubart sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Riliprubart market report also features the SWOT analysis with analyst views for Riliprubart in potential indications.

Methodology

The Riliprubart market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Riliprubart Analytical Perspective by DelveInsight

• In-depth Riliprubart Market Assessment

This Riliprubart sales market forecast report provides a detailed market assessment of Riliprubart for potential indication like Chronic inflammatory demyelinating polyradiculoneuropathy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Riliprubart sales data uptil 2034.

• Riliprubart Clinical Assessment

The Riliprubart market report provides the clinical trials information of Riliprubart for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Riliprubart Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Riliprubart Market Potential & Revenue Forecast

• Projected market size for the Riliprubart and its key indications
• Estimated Riliprubart sales potential (Riliprubart peak sales forecasts)
• Riliprubart Pricing strategies and reimbursement landscape

Riliprubart Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Riliprubart Market positioning compared to existing treatments
• Riliprubart Strengths & weaknesses relative to competitors

Riliprubart Regulatory & Commercial Milestones

• Riliprubart Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Riliprubart Clinical Differentiation

• Riliprubart Efficacy & safety advantages over existing drugs
• Riliprubart Unique selling points

Riliprubart Market Report Highlights

• In the coming years, the Riliprubart market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Riliprubart companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Riliprubart’s dominance.
• Other emerging products for Chronic inflammatory demyelinating polyradiculoneuropathy are expected to give tough market competition to Riliprubart and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Riliprubart in potential indications.
• Analyse Riliprubart cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Riliprubart sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Riliprubart in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Riliprubart? How strong is Riliprubart’s clinical and commercial performance?
• What is Riliprubart’s clinical trial status in each individual indications such as Chronic inflammatory demyelinating polyradiculoneuropathy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Riliprubart Manufacturers?
• What are the key designations that have been granted to Riliprubart for potential indications? How are they going to impact Riliprubart’s penetration in various geographies?
• What is the current and forecasted Riliprubart market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Riliprubart in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Riliprubart for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Riliprubart? What is the duration of therapy and what are the geographical variations in cost per patient?